← Back to headlines
Sobi Reports 24% Revenue Increase in Q1 2026
Swedish Orphan Biovitrum AB (Sobi®) announced its first-quarter 2026 report, showing a 24% rise in revenue driven by strong growth in hematology and immunology. The company maintained its financial forecast for 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
